Portal de investigación
Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques.
Fecha de publicación:
Fecha Ahead of Print:
Autores de CIPF
Participantes ajenos a CIPF
- Pegoraro C
- Domingo-Ortí I
Grupos de Investigación
Abstract
Enhanced targeting approaches will support the treatment of diseases associated with dysfunctional mitochondria, which play critical roles in energy generation and cell survival. Obstacles to mitochondria-specific targeting include the presence of distinct biological barriers and the need to pass through (or avoid) various cell internalization mechanisms. A range of studies have reported the design of mitochondrially-targeted nanomedicines that navigate the complex routes required to influence mitochondrial function; nonetheless, a significant journey lies ahead before mitochondrially-targeted nanomedicines become suitable for clinical use. Moving swiftly forward will require safety studies, in vivo assays confirming effectiveness, and methodologies to validate mitochondria-targeted nanomedicines' subcellular location/activity. From a nanomedicine standpoint, we describe the biological routes involved (from administration to arrival within the mitochondria), the features influencing rational design, and the techniques used to identify/validate successful targeting. Overall, rationally-designed mitochondria-targeted-based nanomedicines hold great promise for precise subcellular therapeutic delivery.
Datos de la publicación
- ISSN/ISSNe:
- 0169-409X, 1872-8294
- Tipo:
- Article
- Páginas:
- 115195-115195
- PubMed:
- 38325562
ADVANCED DRUG DELIVERY REVIEWS ELSEVIER SCIENCE BV
Citas Recibidas en Web of Science: 12
Documentos
- No hay documentos
Filiaciones
Keywords
- Intracellular delivery, Mitochondrial activity and metabolism, Mitochondrially targeted precision nanomedicines, Physico-chemical characterization, Stimuli-responsive nanomedicine, Subcellular targeting
Proyectos asociados
Aproximación sinérgica al desarrollo de terapias para tumores metastásicos y desórdenes neurodegenarativos utilizando conjugados polipetídicos versátiles
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2020
Incorporacion nuevos grupos al CIBER CIBERONC. Punto 3.2 Immunoterapia para tumores sólidos. NOTA: el presupuesto concedido es para le CIBER no para el CIPF
Investigador Principal: MARIA JESUS VICENT DOCON
2022
Nanoplataforma Polipeptídica Multimodal de Precisión para el Tratamiento y Monitorización de Tumores Metastásicos. Colab I-36, I-12, I-63, servicio citómica, uji y gva (Esther Roselló)
Investigador Principal: MARIA JESUS VICENT DOCON
CONSELLERIA DE EDUCACION . 2022
New nanotechnological therapy for Parkinson´s disease: nose to brain delivery of GBA-polymer nanoconjugates
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACIÓN LA CAIXA . 2022
Modelos de transcriptomica espacial y comunicación celular aplicados a la regeneracion tisular y tratamiento en daño de espina dorsal. Coordina Ana Conesa del CSIC, colaboran MJ.Vicent, V.Moreno, A.Alastrue y A.Armiñan del CIPF
CONSELLERIA DE EDUCACION . 2023
MULTISMART, Multi-component Soft Materials Advanced Research Training Network
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2023
Sinergias en descubrimiento de fármacos en España. ES-OPENSCREEN_2
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2023
Long-acting injectables
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2023
Plataforma ISCIII de Biomodelos y Biobancos
Investigador Principal: MARIA JESUS VICENT DOCON
INSTITUTO DE SALUD CARLOS III . 2024
MSCA-Doctoral Network
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2024
ADQUISICIÓN DE EQUIPAMIENTO CIENTÍFICOTÉCNICO
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2024